XTX Topco Ltd Buys New Position in CG Oncology, Inc. (NASDAQ:CGON)

XTX Topco Ltd purchased a new position in shares of CG Oncology, Inc. (NASDAQ:CGON - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 19,996 shares of the company's stock, valued at approximately $573,000.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. JPMorgan Chase & Co. increased its holdings in shares of CG Oncology by 59.1% during the third quarter. JPMorgan Chase & Co. now owns 31,071 shares of the company's stock worth $1,172,000 after purchasing an additional 11,542 shares during the period. China Universal Asset Management Co. Ltd. acquired a new stake in CG Oncology during the fourth quarter worth approximately $411,000. Vanguard Group Inc. increased its stake in CG Oncology by 15.3% during the 4th quarter. Vanguard Group Inc. now owns 5,861,082 shares of the company's stock worth $168,096,000 after acquiring an additional 779,730 shares during the period. Barclays PLC raised its holdings in CG Oncology by 331.1% in the 3rd quarter. Barclays PLC now owns 90,520 shares of the company's stock valued at $3,416,000 after acquiring an additional 69,523 shares in the last quarter. Finally, Franklin Resources Inc. lifted its position in shares of CG Oncology by 8.9% during the 3rd quarter. Franklin Resources Inc. now owns 1,230,193 shares of the company's stock valued at $46,157,000 after acquiring an additional 100,106 shares during the period. Institutional investors and hedge funds own 26.56% of the company's stock.

CG Oncology Price Performance

Shares of CG Oncology stock traded up $0.79 during midday trading on Thursday, reaching $21.52. The company had a trading volume of 1,676,660 shares, compared to its average volume of 733,259. The stock has a fifty day moving average price of $23.85 and a 200 day moving average price of $29.48. The firm has a market cap of $1.64 billion, a PE ratio of -15.15 and a beta of 1.24. CG Oncology, Inc. has a fifty-two week low of $14.80 and a fifty-two week high of $46.99.

CG Oncology (NASDAQ:CGON - Get Free Report) last released its earnings results on Tuesday, March 25th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.11). The business had revenue of $0.46 million for the quarter, compared to analysts' expectations of $0.11 million. CG Oncology had a negative net margin of 10,642.98% and a negative return on equity of 18.97%. As a group, sell-side analysts forecast that CG Oncology, Inc. will post -1.31 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. HC Wainwright reaffirmed a "buy" rating and issued a $75.00 price target on shares of CG Oncology in a research note on Monday, March 31st. TD Cowen initiated coverage on shares of CG Oncology in a research report on Tuesday, January 7th. They set a "buy" rating on the stock. Scotiabank initiated coverage on shares of CG Oncology in a research report on Wednesday, April 16th. They set a "sector perform" rating and a $23.00 price objective for the company. Finally, Morgan Stanley reaffirmed an "overweight" rating and issued a $55.00 target price on shares of CG Oncology in a report on Friday, March 7th. One equities research analyst has rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $59.33.

CG Oncology Company Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.